Peytant Solutions has secured FDA marketing authorization for its AMStent tracheobronchial covered stent system, a novel therapy designed to alleviate pulmonary obstructions caused by cancer. The de novo nod allows the Plymouth, Minnesota-based company to market its AMStent system for treating tracheobronchial strictures produced by malignant neoplasms in adult patients.
The AMStent system represents Peytant's first product offering within its amnion-based covered stent platform. It uniquely combines a minimally invasive catheter delivery system with a stent covered in material derived from amnion. This design aims to address the challenges faced by cancer patients who develop malignant airway obstructions as their disease progresses.
Clinical Application and Benefits
Many patients with cancer experience malignant airway obstructions, necessitating palliative care to improve airflow in the trachea or tracheobronchial tree. The AMStent system facilitates this by dilating the lumen, allowing patients to receive routine airway stents. Peytant reports that the benefits of AMStent include reduced migration, decreased local inflammation and granuloma formation, and diminished mucus accumulation and occlusion.
Expert Commentary
Dr. Craig Walker, founder, president, and medical director of the Cardiovascular Institute of the South in Houma, Louisiana, hailed the system as "a unique option for patients who need it most." John Schorgl, Peytant co-founder and CEO, expressed optimism that the AMStent system will provide a much-needed option for patients suffering from tracheobronchial obstruction due to malignant tumors, with the goal of improving palliative care and quality of life.
